Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Excerpt:
Cells expressing ABL2, CSF1R, and JAK2 fusions have enhanced STAT5 activation, which is inhibited by dasatinib in RCSD1–ABL2 and SSBP2–CSF1R and by ruxolitinib in PAX5–JAK2.